Individualized Vancomycin Dosing with Therapeutic Drug Monitoring and Pharmacokinetic Consultation Service: A Large-Scale Retrospective Observational Study

References

• LevineDP. Vancomycin: a history. Clin Infect Dis. 2006;42(Suppl 1):S5–S12. doi:10.1086/49170916323120
   PubMed Web of Science ®Google Scholar
• HassounA, LindenPK, FriedmanB. Incidence, prevalence, and management of MRSA bacteremia across patient populations-a review of recent developments in MRSA management and treatment. Crit Care. 2017;21(1):211. doi:10.1186/s13054-017-1801-328807042
   PubMed Web of Science ®Google Scholar
• LiuC, BayerA, CosgroveSE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52(3):285–292. doi:10.1093/cid/cir03421217178
   PubMed Web of Science ®Google Scholar
• StevensDL. The role of vancomycin in the treatment paradigm. Clin Infect Dis. 2006;42(Suppl 1):S51–S57. doi:10.1086/49171416323121
   PubMed Web of Science ®Google Scholar
• LöwdinE, OdenholtI, CarsO. In vitro studies of pharmacodynamic properties of vancomycin against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother. 1998;42(10):2739–2744. doi:10.1128/aac.42.10.27399756787
   PubMed Web of Science ®Google Scholar
• RybakM, LomaestroB, RotschaferJC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66(1):82–98. doi:10.2146/ajhp08043419106348
   PubMedGoogle Scholar
• DrusanoGL. Antimicrobial pharmacodynamics: critical interactions of ‘bug and drug’. Nat Rev Microbiol. 2004;2(4):289–300. doi:10.1038/nrmicro86215031728
   PubMed Web of Science ®Google Scholar
• CraigWA. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am. 2003;17(3):479–501. doi:10.1016/s0891-5520(03)00065-514711073
   PubMed Web of Science ®Google Scholar
• RybakMJ, LeJ, LodiseTP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2020;77(11):835–864. doi:10.1093/ajhp/zxaa03632191793
   PubMed Web of Science ®Google Scholar
• CongY, YangS, RaoX. Vancomycin resistant Staphylococcus aureus infections: a review of case updating and clinical features. J Adv Res. 2020;21:169–176. doi:10.1016/j.jare.2019.10.00532071785
   PubMed Web of Science ®Google Scholar
• AppelbaumPC. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin Microbiol Infect. 2006;12(Suppl 1):16–23. doi:10.1111/j.1469-0691.2006.01344.x
   PubMed Web of Science ®Google Scholar
• ÁlvarezR, López CortésLE, MolinaJ, CisnerosJM, PachónJ. Optimizing the Clinical Use of Vancomycin. Antimicrob Agents Chemother. 2016;60(5):2601–2609. doi:10.1128/aac.03147-1426856841
   PubMed Web of Science ®Google Scholar
• BeggEJ, BarclayML, KirkpatrickCM. The therapeutic monitoring of antimicrobial agents. Br J Clin Pharmacol. 2001;52(Suppl 1):35s–43s. doi:10.1046/j.1365-2125.2001.0520s1035.x11564051
   PubMed Web of Science ®Google Scholar
• LevyG. What are narrow therapeutic index drugs? Clin Pharmacol Ther. 1998;63(5):501–505. doi:10.1016/s0009-9236(98)90100-x9630822
   PubMed Web of Science ®Google Scholar
• IwamotoT, KagawaY, KojimaM. Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin. Biol Pharm Bull. 2003;26(6):876–879. doi:10.1248/bpb.26.87612808304
   PubMed Web of Science ®Google Scholar
• YeZK, TangHL, ZhaiSD, CarvajalA. Benefits of therapeutic drug monitoring of vancomycin: a systematic review and meta-analysis. PLoS One. 2013;8(10):e77169. doi:10.1371/journal.pone.007716924204764
   PubMed Web of Science ®Google Scholar
• RobertsJA, NorrisR, PatersonDL, MartinJH. Therapeutic drug monitoring of antimicrobials. Br J Clin Pharmacol. 2012;73(1):27–36. doi:10.1111/j.1365-2125.2011.04080.x21831196
   PubMed Web of Science ®Google Scholar
• AllegaertK, FlintR, SmitsA. Pharmacokinetic modelling and Bayesian estimation-assisted decision tools to optimize vancomycin dosage in neonates: only one piece of the puzzle. Expert Opin Drug Metab Toxicol. 2019;15(9):735–749. doi:10.1080/17425255.2019.165554031402708
   PubMed Web of Science ®Google Scholar
• HeN, SuS, YanY, LiuW, ZhaiS. The benefit of individualized vancomycin dosing via pharmacokinetic tools: a systematic review and meta-analysis. Ann Pharmacother. 2020;54(4):331–343. doi:10.1177/106002801988736331694384
   PubMed Web of Science ®Google Scholar
• MomattinH, ZogheibM, HomoudA, Al-TawfiqJA. Safety and outcome of pharmacy-led vancomycin dosing and monitoring. Chemotherapy. 2016;61(1):3–7. doi:10.1159/00044060726555724
   PubMed Web of Science ®Google Scholar
• MonteiroJF, HahnSR, GonçalvesJ, FrescoP. Vancomycin therapeutic drug monitoring and population pharmacokinetic models in special patient subpopulations. Pharmacol Res Perspect. 2018;6(4):e00420. doi:10.1002/prp2.42030156005
   PubMed Web of Science ®Google Scholar
• MuklewiczJD, SteuberTD, EdwardsJD. Evaluation of area under the concentration-time curve-guided vancomycin dosing with or without piperacillin-tazobactam on the incidence of acute kidney injury. Int J Antimicrob Agents. 2020;57:106234. doi:10.1016/j.ijantimicag.2020.10623433232734
   PubMed Web of Science ®Google Scholar
• RotschaferJC, CrossleyK, ZaskeDE, MeadK, SawchukRJ, SolemLD. Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations. Antimicrob Agents Chemother. 1982;22(3):391–394. doi:10.1128/aac.22.3.3917137982
   PubMed Web of Science ®Google Scholar
• StoesselAM, HaleCM, SeaburyRW, MillerCD, SteeleJM. The impact of AUC-based monitoring on pharmacist-directed vancomycin dose adjustments in complicated methicillin-resistant Staphylococcus aureus infection. J Pharm Pract. 2019;32(4):442–446. doi:10.1177/089719001876456429554847
   PubMed Web of Science ®Google Scholar
• TruongJ, SmithSR, VeilletteJJ, ForlandSC. Individualized pharmacokinetic dosing of vancomycin reduces time to therapeutic trough concentrations in critically ill patients. J Clin Pharmacol. 2018;58(9):1123–1130. doi:10.1002/jcph.127329957824
   PubMed Web of Science ®Google Scholar
• WallenburgE, Ter HeineR, SchoutenJA, BrüggemannRJM. Personalised antimicrobial dosing: standing on the shoulders of giants. Int J Antimicrob Agents. 2020;56:106062. doi:10.1016/j.ijantimicag.2020.10606232574792
   PubMed Web of Science ®Google Scholar
• ZhaoW, LopezE, BiranV, DurrmeyerX, FakhouryM, Jacqz-AigrainE. Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic drug monitoring. Arch Dis Child. 2013;98(6):449–453. doi:10.1136/archdischild-2012-30276523254142
   PubMed Web of Science ®Google Scholar
• StockerSL, CarlandJE, ReuterSE, et al. Evaluation of a pilot vancomycin precision dosing advisory service on target exposure attainment using an interrupted time series analysis. Clin Pharmacol Ther. 2020. doi:10.1002/cpt.2113
   Web of Science ®Google Scholar
• HongJ, KropLC, JohnsT, PaiMP. Individualized vancomycin dosing in obese patients: a two-sample measurement approach improves target attainment. Pharmacotherapy. 2015;35(5):455–463. doi:10.1002/phar.158826011138
   PubMed Web of Science ®Google Scholar
• RybakMJ, LomaestroBM, RotschaferJC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis. 2009;49(3):325–327. doi:10.1086/60087719569969
   PubMed Web of Science ®Google Scholar
• AbulfathiAA, ChirehwaM, RosenkranzB, DecloedtEH. Evaluation of the effectiveness of dose individualization to achieve therapeutic vancomycin concentrations. J Clin Pharmacol. 2018;58(9):1134–1139. doi:10.1002/jcph.125429746714
   PubMed Web of Science ®Google Scholar
• CardileAP, TanC, LustikMB, et al. Optimization of time to initial vancomycin target trough improves clinical outcomes. Springerplus. 2015;4:364. doi:10.1186/s40064-015-1146-926203410
   PubMedGoogle Scholar
• CrumbyT, RinehartE, CarbyMC, KuhlD, TalatiAJ. Pharmacokinetic comparison of nomogram-based and individualized vancomycin regimens in neonates. Am J Health Syst Pharm. 2009;66(2):149–153. doi:10.2146/ajhp08012119139479
   PubMed Web of Science ®Google Scholar
• GrimsleyC, ThomsonAH. Pharmacokinetics and dose requirements of vancomycin in neonates. Arch Dis Child Fetal Neonatal Ed. 1999;81(3):F221–F227. doi:10.1136/fn.81.3.f22110525029
   PubMed Web of Science ®Google Scholar
• HiranoR, SakamotoY, KitazawaJ, YamamotoS, TachibanaN. Pharmacist-managed dose adjustment feedback using therapeutic drug monitoring of vancomycin was useful for patients with methicillin-resistant Staphylococcus aureus infections: a single institution experience. Infect Drug Resist. 2016;9:243–252. doi:10.2147/idr.S10948527789965
   PubMed Web of Science ®Google Scholar
• IrikuraM, FujiyamaA, SaitaF, et al. Evaluation of the vancomycin dosage regimen based on serum creatinine used in the neonatal intensive care unit. Pediatr Int. 2011;53(6):1038–1044. doi:10.1111/j.1442-200X.2011.03441.x21810150
   PubMed Web of Science ®Google Scholar
• KomotoA, MaigumaT, TeshimaD, SugiyamaT, HarukiY. Effects of pharmacist intervention in Vancomycin treatment for patients with bacteremia due to Methicillin-resistant Staphylococcus aureus. PLoS One. 2018;13(9):e0203453. doi:10.1371/journal.pone.020345330188918
   PubMed Web of Science ®Google Scholar
• MasudaN, MaigumaT, KomotoA, et al. Impact of pharmacist intervention on preventing nephrotoxicity from vancomycin. Int J Clin Pharmacol Ther. 2015;53(4):284–291. doi:10.5414/cp20227425740266
   PubMed Web of Science ®Google Scholar
• MillerCL, WinansSA, VeilletteJJ, ForlandSC. Use of individual pharmacokinetics to improve time to therapeutic vancomycin trough in pediatric oncology patients. J Pediatr Pharmacol Ther. 2018;23(2):92–99. doi:10.5863/1551-6776-23.2.9229720909
   PubMedGoogle Scholar
• ThieseMS. Observational and interventional study design types; an overview. Biochem Med (Zagreb). 2014;24(2):199–210. doi:10.11613/bm.2014.02224969913
   PubMed Web of Science ®Google Scholar
• HoAMH, PhelanR, MizubutiGB, et al. Bias in before-after studies: narrative overview for anesthesiologists. Anesth Analg. 2018;126(5):1755–1762. doi:10.1213/ane.000000000000270529239959
   PubMed Web of Science ®Google Scholar
• HoKK, ThiessenJJ, BrysonSM, GreenbergML, EinarsonTR, LesonCL. Challenges in comparing treatment outcome from a prospective with that of a retrospective study: assessing the merit of gentamicin therapeutic drug monitoring in pediatric oncology. Ther Drug Monit. 1994;16(3):238–247. doi:10.1097/00007691-199406000-000038085278
   PubMed Web of Science ®Google Scholar
• DorajooSR, WinataCL, GohJHF, et al. Optimizing vancomycin dosing in chronic kidney disease by deriving and implementing a web-based tool using a population pharmacokinetics analysis. Front Pharmacol. 2019;10:641. doi:10.3389/fphar.2019.0064131244657
   PubMed Web of Science ®Google Scholar
• SuzukiY, KawasakiK, SatoY, et al. Is peak concentration needed in therapeutic drug monitoring of vancomycin? A pharmacokinetic-pharmacodynamic analysis in patients with methicillin-resistant staphylococcus aureus pneumonia. Chemotherapy. 2012;58(4):308–312. doi:10.1159/00034316223147106
   PubMed Web of Science ®Google Scholar
• LodiseTP, DrusanoGL, ZasowskiE, et al. Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough? Clin Infect Dis. 2014;59(5):666–675. doi:10.1093/cid/ciu39824867791
   PubMed Web of Science ®Google Scholar
• LodiseTP, PatelN, LomaestroBM, RodvoldKA, DrusanoGL. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis. 2009;49(4):507–514. doi:10.1086/60088419586413
   PubMed Web of Science ®Google Scholar
• NeelyMN, YounG, JonesB, et al. Are vancomycin trough concentrations adequate for optimal dosing? Antimicrob Agents Chemother. 2014;58(1):309–316. doi:10.1128/aac.01653-1324165176
   PubMed Web of Science ®Google Scholar
• FinchNA, ZasowskiEJ, MurrayKP, et al. A quasi-experiment to study the impact of vancomycin area under the concentration-time curve-guided dosing on vancomycin-associated nephrotoxicity. Antimicrob Agents Chemother. 2017;61(12). doi:10.1128/aac.01293-17
   Web of Science ®Google Scholar
• BellosI, DaskalakisG, PergialiotisV. Relationship of vancomycin trough levels with acute kidney injury risk: an exposure-toxicity meta-analysis. J Antimicrob Chemother. 2020;75(10):2725–2734. doi:10.1093/jac/dkaa18432417905
   PubMed Web of Science ®Google Scholar
• ChavadaR, GhoshN, SandaraduraI, MaleyM, Van HalSJ. Establishment of an AUC(0-24) threshold for nephrotoxicity is a step towards individualized vancomycin dosing for methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2017;61(5). doi:10.1128/aac.02535-16
   Web of Science ®Google Scholar
• The periodic health examination. Canadian task force on the periodic health examination. Can Med Assoc J. 1979;121(9):1193–1254.115569
   PubMedGoogle Scholar
• LeeBV, FongG, BolarisM, et al. Cost-benefit analysis comparing trough, two-level AUC, and Bayesian AUC dosing for vancomycin. Clin Microbiol Infect. 2020. doi:10.1016/j.cmi.2020.11.008
   Web of Science ®Google Scholar
• NeelyMN, KatoL, YounG, et al. Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing. Antimicrob Agents Chemother. 2018;62(2). doi:10.1128/aac.02042-17
   Web of Science ®Google Scholar
• FlanneryAH, DelozierNL, EffoeSA, WallaceKL, CookAM, BurgessDS. First-dose vancomycin pharmacokinetics versus empiric dosing on area-under-the-curve target attainment in critically ill patients. Pharmacotherapy. 2020;40:1210–1218. doi:10.1002/phar.248633176005
   PubMed Web of Science ®Google Scholar
• DilworthTJ, SchulzLT, RoseWE. Vancomycin advanced therapeutic drug monitoring: an exercise in futility or virtuous endeavor to improve drug efficacy and safety? Clin Infect Dis. 2020. doi:10.1093/cid/ciaa1354
   Web of Science ®Google Scholar
• KufelWD, SeaburyRW, MogleBT, BeccariMV, ProbstLA, SteeleJM. Readiness to implement vancomycin monitoring based on area under the concentration-time curve: a cross-sectional survey of a national health consortium. Am J Health Syst Pharm. 2019;76(12):889–894. doi:10.1093/ajhp/zxz07031063582
   PubMed Web of Science ®Google Scholar
• FlanneryAH, HammondDA, OylerDR, et al. Vancomycin dosing practices among critical care pharmacists: a survey of society of critical care medicine pharmacists. Infect Dis (Auckl). 2020;13:1178633720952078. doi:10.1177/117863372095207833029073
   PubMedGoogle Scholar
• ChoiR, WooHI, ParkHD, LeeSY. A nationwide utilization survey of therapeutic drug monitoring for five antibiotics in South Korea. Infect Drug Resist. 2019;12:2163–2173. doi:10.2147/idr.S20878331410036
   PubMed Web of Science ®Google Scholar
• TeoBW, ZhangL, GuhJ-Y, et al. Glomerular filtration rates in asians. Adv Chronic Kidney Dis. 2018;25(1):41–48. doi:10.1053/j.ackd.2017.10.00529499886
   PubMed Web of Science ®Google Scholar
• JoyceEL, Kane-GillSL, FuhrmanDY, KellumJA. Drug-associated acute kidney injury: who’s at risk? Pediatr Nephrol. 2017;32(1):59–69. doi:10.1007/s00467-016-3446-x27338726
   PubMed Web of Science ®Google Scholar
• FilipponeEJ, KraftWK, FarberJL. The Nephrotoxicity of Vancomycin. Clin Pharmacol Ther. 2017;102(3):459–469. doi:10.1002/cpt.72628474732
   PubMed Web of Science ®Google Scholar
• CovveyJR, EricksonO, FiumaraD, et al. Comparison of vancomycin area-under-the-curve dosing versus trough target-based dosing in obese and nonobese patients with methicillin-resistant Staphylococcus aureus bacteremia. Ann Pharmacother. 2020;54(7):644–651. doi:10.1177/106002801989710031888350
   PubMed Web of Science ®Google Scholar
• MengL, WongT, HuangS, et al. Conversion from vancomycin trough concentration-guided dosing to area under the curve-guided dosing using two sample measurements in adults: implementation at an academic medical center. Pharmacotherapy. 2019;39(4):433–442. doi:10.1002/phar.223430739349
   PubMed Web of Science ®Google Scholar
• OdaK, JonoH, NosakaK, SaitoH. Reduced nephrotoxicity with vancomycin therapeutic drug monitoring guided by area under the concentration-time curve against a trough 15–20 μg/mL concentration. Int J Antimicrob Agents. 2020;56(4):106109. doi:10.1016/j.ijantimicag.2020.10610932721597
   PubMed Web of Science ®Google Scholar
• PeaF, BertolissiM, Di SilvestreA, PozD, GiordanoF, FurlanutM. TDM coupled with Bayesian forecasting should be considered an invaluable tool for optimizing vancomycin daily exposure in unstable critically ill patients. Int J Antimicrob Agents. 2002;20(5):326–332. doi:10.1016/s0924-8579(02)00188-712431867
   PubMed Web of Science ®Google Scholar